Benjamin Leslie, DO
Internal Medicine · Petersburg, WVNPI 1902165228
Payments from drug & device makers
Across 307 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$821
- Novo Nordisk$716
- Lilly USA, LLC$462
- Amgen$387
- AbbVie$310
- Novartis$275
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,697100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $821 |
| Novo Nordisk | 57 | $716 |
| Lilly USA, LLC | 32 | $462 |
| Amgen | 26 | $387 |
| AbbVie(2 entities) | 24 | $310 |
| Novartis | 18 | $275 |
| Boehringer Ingelheim | 18 | $267 |
| Johnson & Johnson | 16 | $266 |
| Amarin Pharma, Inc. | 15 | $249 |
| E.r. Squibb & Sons, L.L.C. | 15 | $245 |
| Phathom Pharmaceuticals, Inc. | 7 | $118 |
| Pfizer | 7 | $114 |
| Sanofi-aventis U.S. LLC | 4 | $58 |
| Dexcom, Inc. | 3 | $56 |
| Exact Sciences | 2 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Bayer | 2 | $34 |
| GSK | 2 | $31 |
| Merck | 2 | $28 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| Abbott | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Heartflow, Inc. | 1 | $14 |
| Alkermes, Inc. | 1 | $13 |
How this compares
$4,717 in reported general payments places this provider in the 85th percentile of 573 internal medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 190 | $183,925 |
| JardianceEmpagliflozin | 88 | $112,738 |
| OzempicSemaglutide | 76 | $101,525 |
| XareltoRivaroxaban | 83 | $83,928 |
| MounjaroTirzepatide | 65 | $76,616 |
| FarxigaDapagliflozin Propanediol | 58 | $63,719 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $54,207 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $37,221 |
| JanuviaSitagliptin Phosphate | 23 | $32,535 |
| TrulicityDulaglutide | 21 | $27,055 |
| RybelsusSemaglutide | 16 | $26,491 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $15,552 |
| LinzessLinaclotide | 11 | $14,315 |
| EntrestoSacubitril/Valsartan | 16 | $13,513 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,669 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $114 | $186,885203 claims |
| Novo NordiskOzempic, Rybelsus | $716 | $128,01592 claims |
| Boehringer IngelheimJardiance, Tradjenta | $267 | $123,020107 claims |
| Lilly USA, LLCMounjaro, Trulicity | $462 | $103,67286 claims |
| Johnson & JohnsonXarelto | $266 | $83,92883 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $821 | $80,07494 claims |
| GSKTrelegy Ellipta | $31 | $54,20772 claims |
| MerckJanuvia | $28 | $32,53523 claims |
| AbbVieLinzess, Synthroid | $310 | $17,05139 claims |
| NovartisEntresto | $275 | $13,51316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 573 internal medicine providers in West Virginia.
Other internal medicine in Petersburg
- Stephen ThompsonPetersburg$5K
- Ward PaineMorgantown$5.1M
- William ChapmanCharleston$1.7M
- Mustafa AwiliHuntington$906K
- David PickeringParkersburg$694K
- Laura DavissonMorgantown$118K
- Michael BrumageClendenin$87K
- Govind PatelFairmont$59K
- Lynn SmithLewisburg$31K
- Bisher MustafaHuntington$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.